SBIR/STTR Research Award

Accelerating Wound Healing through RNAi

Award identifier aa3af99826dfd161ac2ec19751eeedd0ad60855b6ef7b59eb8961b5bcb85f667Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,406,957

Program and phase

SBIR · Phase II

Award year

2014

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Somagenics, Inc.
Proposal award date
2014-09-24
Contract end date
2016-08-31
UEI
NWMCAECH9RX7
Solicitation number
PA13-234
Topic code
300

Research abstract

DESCRIPTION provided by applicant The growing populations of the elderly and those with type II diabetes are at high risk for developing chronic wounds that are slow to heal Effective therapeutics to promote wound healing could significantly improve the lives of these people Normal wound healing involves a coordinated cascade of events that are stimulated in part by the hypoxia that results from injury to the vasculature at the wound site These events include angiogenesis vasculogenesis macrophage recruitment inhibition of apoptosis and the expansion and mobilization of fibroblasts and keratinocytes for re epithelializaton In chronic wounds the normal response to hypoxia is impaired and many of these cellular processes are hindered In this project we have proposed to modulate three key targets involved these processes using a combination of RNA interference RNAi and antisense approaches In Phase I we identified oligonucleotides that reduce levels of two of these targets a protein and a microRNA miRNA increase levels of downstream factors promoting angiogenesis and increase the mobility of keratinocytes One of these inhibitors uses Somagenicsandapos proprietary sshRNAandquot short synthetic hairpin RNA design which has been shown to be highly effective in treating chimeric mice infected with hepatitis C virus In Phase II we will test the effects of modulating levels of the third target which is also a miRNA and evaluate the biological effects of these oligonucleotides when used individually or in combinations in tissue culture models relevant to wound healing We will then test the in vivo efficacy of these three oligonucleotides under normal as well as compromised ischemic and diabetic wound healing conditions in mice To enhance in vivo stability and eliminate any undesirable immune stimulation all three oligonucleotides will be chemically modified In addition several different methods for delivering RNA to tissue will be evaluated for efficacy in speeding wound closure and effect on the targets of the oligonucleotides as well as downstream factors involved in wound healing This novel three pronged approach to modulating the factors involved in wound healing could represent an effective strategy for treatment of chronic wounds and potentially also acute wounds PUBLIC HEALTH RELEVANCE Therapeutics that promote rapid wound closure and healing and reduce the risk of infection would be of great benefit to patients with chronic or slow healing wounds particularly diabetics The oligonucleotide based therapeutics to be developed in this program will probably not require refrigeration and they are expected to produce relatively long lasting therapeutic effects allowing for infrequent dosing These agents could provide a significant health benefit where healing is impaired including chronic wounds pressure ulcers venous ulcers and especially diabetic ulcers for which there is enormous medical need A product that successfully promotes healing of these wounds could substantially reduce the burden of healthcare costs

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

39 SBIR/STTR records share this UEI (1994–2020). Reported award amounts total $23,258,381. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.